Amygdala Neurofeedback for Borderline Personality Disorder

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of Pittsburgh, Pittsburgh, PA
Borderline Personality Disorder+1 More
Amygdala Neurofeedback - Behavioral
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

The goal of this study is to evaluate whether rtfMRI-nf training to increase the amygdala response to positive memories may serve as an intervention for borderline personality disorder.

Eligible Conditions

  • Borderline Personality Disorder

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Borderline Personality Disorder

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Baseline vs 12 weeks

Baseline vs 12 weeks
Change from Baseline in Beck Depression Inventory at 12 weeks
Change from Baseline in Borderline Scale from the Personality Assessment Inventory at 12 weeks

Trial Safety

Safety Progress

1 of 3

Other trials for Borderline Personality Disorder

Trial Design

1 Treatment Group

Amygdala Neurofeedback
1 of 1
Experimental Treatment

100 Total Participants · 1 Treatment Group

Primary Treatment: Amygdala Neurofeedback · No Placebo Group · N/A

Amygdala Neurofeedback
Behavioral
Experimental Group · 1 Intervention: Amygdala Neurofeedback · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline vs 12 weeks

Trial Background

Prof. Kymberly Young, Associate Professor
Principal Investigator
University of Pittsburgh
Closest Location: University of Pittsburgh · Pittsburgh, PA
Photo of University of Pittsburgh Medical Center   1Photo of University of Pittsburgh Medical Center   2Photo of University of Pittsburgh Medical Center  3
2004First Recorded Clinical Trial
1 TrialsResearching Borderline Personality Disorder
646 CompletedClinical Trials

Eligibility Criteria

Age 18 - 65 · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.